{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:05:14Z","timestamp":1793387114797,"version":"4.5.0"},"reference-count":66,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","award":["Health Research Scholar Award - Quon BS"],"award-info":[{"award-number":["Health Research Scholar Award - Quon BS"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","award":["Health Research Trainee Award - Franciosi AN"],"award-info":[{"award-number":["Health Research Trainee Award - Franciosi AN"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2022,9,5]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>People living with cystic fibrosis have an increased risk of lung infection with nontuberculous mycobacteria (NTM), the prevalence of which is reportedly increasing. We conducted a systematic review of the literature to estimate the burden (prevalence and incidence) of NTM in the cystic fibrosis population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Electronic databases, registries and grey literature sources were searched for cohort and cross-sectional studies reporting epidemiological measures (incidence and prevalence) of NTM infection or NTM pulmonary disease in cystic fibrosis. The last search was conducted in September 2021; we included reports published since database creation and registry reports published since 2010. The methodological quality of studies was appraised with the Joanna Briggs Institute tool. A random effects meta-analysis was conducted to summarise the prevalence of NTM infection, and the remaining results are presented in a narrative synthesis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This review included 95 studies. All 95 studies reported on NTM infection, and 14 of these also reported on NTM pulmonary disease. The pooled estimate for the point prevalence of NTM infection was 7.9% (95% CI 5.1\u201312.0%). In meta-regression, sample size and geographical location of the study modified the estimate. Longitudinal analysis of registry reports showed an increasing trend in NTM infection prevalence between 2010 and 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The overall prevalence of NTM infection in cystic fibrosis is 7.9% and is increasing over time based on international registry reports. Future studies should report screening frequency, microbial identification methods and incidence rates of progression from NTM infection to pulmonary disease.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00336-2022","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T14:37:27Z","timestamp":1663857447000},"page":"00336-2022","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["Global burden of nontuberculous mycobacteria in the cystic fibrosis population: a systematic review and meta-analysis"],"prefix":"10.1183","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5589-2945","authenticated-orcid":false,"given":"Miguel D.","family":"Prieto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosaab E.","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4241-8718","authenticated-orcid":false,"given":"Alessandro N.","family":"Franciosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"2024101711422784000_9.1.00336-2022.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60327-5"},{"key":"2024101711422784000_9.1.00336-2022.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2015.10.002"},{"key":"2024101711422784000_9.1.00336-2022.3","unstructured":"Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2019 Annual Data Report. Bethesda, MD Cystic Fibrosis Foundation, 2020."},{"key":"2024101711422784000_9.1.00336-2022.4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0039-1698464","article-title":"Microbiology of cystic fibrosis airway disease","volume":"40","author":"Blanchard","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"2024101711422784000_9.1.00336-2022.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2014.10.003"},{"key":"2024101711422784000_9.1.00336-2022.6","doi-asserted-by":"crossref","first-page":"5.1.11","DOI":"10.1128\/microbiolspec.TNMI7-0024-2016","article-title":"Nontuberculous mycobacteria-overview","volume":"5","author":"Koh","year":"2017","journal-title":"Microbiol Spectr"},{"key":"2024101711422784000_9.1.00336-2022.7","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207360"},{"key":"2024101711422784000_9.1.00336-2022.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.12.001"},{"key":"2024101711422784000_9.1.00336-2022.9","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201309-310OC"},{"key":"2024101711422784000_9.1.00336-2022.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201111-2016OC"},{"key":"2024101711422784000_9.1.00336-2022.11","doi-asserted-by":"publisher","DOI":"10.3201\/eid1911.130737"},{"key":"2024101711422784000_9.1.00336-2022.12","first-page":"1069","article-title":"Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea","volume":"14","author":"Park","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024101711422784000_9.1.00336-2022.13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-0676"},{"key":"2024101711422784000_9.1.00336-2022.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.05.008"},{"key":"2024101711422784000_9.1.00336-2022.15","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000714"},{"key":"2024101711422784000_9.1.00336-2022.16","doi-asserted-by":"crossref","unstructured":"Aromataris E , Munn Z . JBI Reviewer's Manual. Adelaide, Joanna Briggs Institute, 2019.","DOI":"10.46658\/JBIRM-19-01"},{"key":"2024101711422784000_9.1.00336-2022.17","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000054"},{"key":"2024101711422784000_9.1.00336-2022.18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2046-4053-4-6","article-title":"Better duplicate detection for systematic reviewers: evaluation of systematic review assistant-deduplication module","volume":"4","author":"Rathbone","year":"2015","journal-title":"Syst Rev"},{"key":"2024101711422784000_9.1.00336-2022.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.06.039"},{"key":"2024101711422784000_9.1.00336-2022.20","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-01082-z"},{"key":"2024101711422784000_9.1.00336-2022.21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","article-title":"The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence","volume":"3","author":"Munn","year":"2014","journal-title":"Int J Health Policy Manag"},{"key":"2024101711422784000_9.1.00336-2022.22","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i11"},{"key":"2024101711422784000_9.1.00336-2022.23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and web application for visualising risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2020","journal-title":"Res Synth Methods"},{"key":"2024101711422784000_9.1.00336-2022.24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jrsm.1348","article-title":"Seriously misleading results using inverse of Freeman\u2013Tukey double arcsine transformation in meta-analysis of single proportions","volume":"10","author":"Schwarzer","year":"2019","journal-title":"Res Synth Methods"},{"key":"2024101711422784000_9.1.00336-2022.25","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1002\/hsr2.178","article-title":"Arcsine-based transformations for meta-analysis of proportions: pros, cons, and alternatives","volume":"3","author":"Lin","year":"2020","journal-title":"Health Sci Rep"},{"key":"2024101711422784000_9.1.00336-2022.26","doi-asserted-by":"publisher","DOI":"10.1097\/ede.0000000000001232"},{"key":"2024101711422784000_9.1.00336-2022.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.03.003"},{"key":"2024101711422784000_9.1.00336-2022.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2024101711422784000_9.1.00336-2022.29","unstructured":"The Brazilian Cystic Fibrosis Study Group . The Brazilian Cystic Fibrosis Patient Registry 2017 Annual Report. http:\/\/www.gbefc.org.br\/ckfinder\/userfiles\/files\/REBRAFC_2017_EN.pdf Date last accessed: 10 February 2022."},{"key":"2024101711422784000_9.1.00336-2022.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(08)80052-2"},{"key":"2024101711422784000_9.1.00336-2022.31","unstructured":"Ruseckaite R , Ahern S , Ranger T , et al. The Australian Cystic Fibrosis Data Registry Annual Report, 2017. Melbourne, Dept of Epidemiology and Preventive Medicine Monash University, 2019."},{"key":"2024101711422784000_9.1.00336-2022.32","doi-asserted-by":"publisher","DOI":"10.3201\/eid\/1907.120615"},{"key":"2024101711422784000_9.1.00336-2022.33","unstructured":"Zolin A , Orenti A , Naehrlich L , et al. 2018 European Cystic Fibrosis Society Patient Registry Annual Data Report. 2020. Available from: https:\/\/www.ecfs.eu\/projects\/ecfs-patient-registry\/annual-reports."},{"key":"2024101711422784000_9.1.00336-2022.34","unstructured":"Cystic Fibrosis Canada . The Canadian Cystic Fibrosis Registry 2019 Annual Data Report. 2021. Available from: https:\/\/www.cysticfibrosis.ca\/about-us\/publications-and-financials"},{"key":"2024101711422784000_9.1.00336-2022.35","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21106"},{"key":"2024101711422784000_9.1.00336-2022.36","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01257-09"},{"key":"2024101711422784000_9.1.00336-2022.37","doi-asserted-by":"publisher","DOI":"10.3109\/00365549409011815"},{"key":"2024101711422784000_9.1.00336-2022.38","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.7.3467-3470.2005"},{"key":"2024101711422784000_9.1.00336-2022.39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jctube.2018.07.003","article-title":"Comparison of the RGM medium and the mycobacterial growth indicator tube automated system for isolation of non-tuberculous mycobacteria from sputum samples of cystic fibrosis patients in Belgium","volume":"13","author":"Scohy","year":"2018","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2024101711422784000_9.1.00336-2022.40","doi-asserted-by":"publisher","DOI":"10.1378\/chest.103.4.1096"},{"key":"2024101711422784000_9.1.00336-2022.41","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1164\/rccm.200207-678OC","article-title":"Nontuberculous mycobacteria: I: Multicenter prevalence study in cystic fibrosis","volume":"167","author":"Olivier","year":"2003","journal-title":"Ame J Respir Crit Care Med"},{"key":"2024101711422784000_9.1.00336-2022.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2007.06.006"},{"key":"2024101711422784000_9.1.00336-2022.43","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02423-16"},{"key":"2024101711422784000_9.1.00336-2022.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.05.002"},{"key":"2024101711422784000_9.1.00336-2022.45","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-006-2597-0"},{"key":"2024101711422784000_9.1.00336-2022.46","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jiac.2016.04.010","article-title":"Nontuberculous mycobacteria in cystic fibrosis patients on the Island of Gran Canaria. A population study","volume":"22","author":"Campos-Herrero","year":"2016","journal-title":"J Infect Chemother"},{"key":"2024101711422784000_9.1.00336-2022.47","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.6.676"},{"key":"2024101711422784000_9.1.00336-2022.48","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00038-17"},{"key":"2024101711422784000_9.1.00336-2022.49","doi-asserted-by":"crossref","first-page":"E120","DOI":"10.1097\/INF.0000000000002999","article-title":"High prevalence of nontuberculous mycobacteria in cystic fibrosis patients in tropical French reunion Island","volume":"40","author":"Ho","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"2024101711422784000_9.1.00336-2022.50","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-003-0195-9"},{"key":"2024101711422784000_9.1.00336-2022.51","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jcf.2019.08.006","article-title":"Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European Cystic Fibrosis Society patient registry","volume":"19","author":"Hatziagorou","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024101711422784000_9.1.00336-2022.52","first-page":"303","article-title":"Epidemiology of nontuberculous mycobacterial infections and associated macrolide use among persons with cystic fibrosis","volume":"48","author":"Binder","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"2024101711422784000_9.1.00336-2022.53","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"2024101711422784000_9.1.00336-2022.54","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00549-14"},{"key":"2024101711422784000_9.1.00336-2022.55","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-204260"},{"key":"2024101711422784000_9.1.00336-2022.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.06.009"},{"key":"2024101711422784000_9.1.00336-2022.57","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-15-41"},{"key":"2024101711422784000_9.1.00336-2022.58","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1002\/ppul.23790","article-title":"Data that empower: the success and promise of CF patient registries","volume":"52","author":"Fink","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2024101711422784000_9.1.00336-2022.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2024101711422784000_9.1.00336-2022.60","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jcf.2017.01.017","article-title":"High incidence of non-tuberculous mycobacteria-positive cultures among adolescent with cystic fibrosis","volume":"16","author":"Cavalli","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2024101711422784000_9.1.00336-2022.61","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","article-title":"Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008\u20132015","volume":"17","author":"Winthrop","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2024101711422784000_9.1.00336-2022.62","doi-asserted-by":"publisher","DOI":"10.3201\/eid2503.181597"},{"key":"2024101711422784000_9.1.00336-2022.63","doi-asserted-by":"crossref","first-page":"fty051","DOI":"10.1093\/femspd\/fty051","article-title":"Prevalence and clinical outcomes of nontuberculous mycobacteria in a Brazilian cystic fibrosis reference center","volume":"76","author":"Aiello","year":"2018","journal-title":"Pathog Dis"},{"key":"2024101711422784000_9.1.00336-2022.64","unstructured":"Nick JA . PREDICT trial: PRospective evaluation of NTM disease in CysTic fibrosis. ClinicalTrials.gov identifier: NCT02073409 . 2021. Date last accessed: 29 November 2021."},{"key":"2024101711422784000_9.1.00336-2022.65","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1002\/ppul.24522","article-title":"Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy","volume":"54","author":"Saiman","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"2024101711422784000_9.1.00336-2022.66","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2925"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00336-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:21:04Z","timestamp":1740374464000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00336-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,3]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1183\/23120541.00336-2022"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00336-2022","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}